In colon cancer patients, the anti-parasitic drug nitazoxanide (NTZ) targets PADI2 to stabilize PADI2, which increases the citrullination of β-catenin protein in cancer cells and blocks the Wnt/β-catenin signaling pathway, thereby inhibiting the growth of cancer cells [144]. The gene discussed is PADI2; the disease is malignant colon neoplasm.